PNIBLOG

brain-tumor-clinical-trials

We have added a new clinical trial and a dose expansion cohort to our roster of brain tumor clinical trials at the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.

TRIALS OPEN FOR ENROLLMENT:

New Trial
Triphase MRZ-112 (NCT02903069): Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer. Download pdf flyer

Dose-Expansion Cohort
Triphase MRZ-108 (NCT02330562): Phase 2 Trial of Single Agent Marizomib in Progressive or Recurrent Grade IV Malignant Glioma. Download pdf flyer

 

ONGOING TRIALS:  

Primary Brain Tumor

AbbVie / RTOG (NCT02573324): A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification. Download pdf flyer

Boehringer Ingelheim (NCT02423525): A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer. Download pdf flyer

Inspyr Therapeutics (NCT02876003): Efficacy, Safety and CNS Exposure of G-202 in Patients with PSMA-Positive Recurrent or Progressive Glioblastoma. Download pdf flyer

ImmunoCellular (NCT02546102): A Phase III Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma following Resection and Concomitant TMZ Chemoradiotherapy. Download pdf flyer

Nativis (NCT02296580): A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM). Download pdf flyer

Orbus Therapeutics (NCT02796261): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. Download pdf flyer

 

Brain Metastases

Boehringer Ingelheim (NCT02423525): A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain CancerDownload pdf flyer

Eli Lilly and Company (NCT02308020): A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma. Download pdf flyer 

EpiCentRX (NCT02215512): Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM). Download pdf flyer

Kadmon (NCT02616393): Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases. Download pdf flyer

 

Investigators:
Achal S. Achrol, MD
Garni Barkhoudarian, MD
Daniel Kelly, MD
Santosh Kesari MD, PhD, FANA, FAAN
Steven O’Day, MD

Clinical Trial Team:
Najee Boucher, CRA  |  310-582-7460
Jaya M. Gill, RN, BSN  |  310-582-7437
Annie Heng, RN, BSN   |  310-582-7457
Tiffany Juarez, PhD
Marlon Garzo Saria, PhD, RN, AOCNS, FAAN

 

For more information, please contact the Neuro-oncology Clinical Trial Team at:
e-mail: neuro.oncology@jwci.org
phone: 310-829-8265